Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744229 | 0.86 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2617526 | 0.85 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7943600 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8516375 | 0.82 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL16485222 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL6129269 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17805715 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29609169 | 0.78 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| Isothiocyanate SCHEMBL30858893 | 0.77 | FABP5 (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| Isothiocyanate SCHEMBL29261606 | 0.77 | FABP5 (0.51) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352656-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | PEPTOMER THERAPEUTICS PRIVATE LTD (IN) | 2025-11-20 | — | — | US | claimed |
| EP-4525827-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | Peptomer Therapeutics Private Limited (IN) | 2025-03-26 | — | — | EP | claimed |
| WO-2023209728-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | PEPTOMER THERAPEUTICS PRIVATE LIMITED (IN) | 2023-11-02 | — | — | WO | claimed |
| US-20020049320-A1 | 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof | AMERICAN CYANAMID COMPANY | 2002-04-25 | — | — | US | claimed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4704854-A2 | PRMT INHIBITOR COMPOUNDS AND THE USES THEREOF | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250352656-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | PEPTOMER THERAPEUTICS PRIVATE LTD (IN) | 2025-11-20 | — | — | US | disclosed |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | GENENTECH, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2002004407-A2 | 7-SUBSTITUTED TETRACYCLINE COMPOUNDS | TRUSTEES OF TUFTS COLLEGE (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004406-A2 | 9-SUBSTITUTED MINOCYCLINE COMPOUNDS | TRUSTEES OF TUFTS COLLEGE (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001087882-A2 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087038-A2 | β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001083478-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001074761-A1 | 7-AND 9-CARBAMATE, UREA, THIOUREA, THIOCARBAMATE, AND HETEROARYL-AMINO SUBSTITUTED TETRACYCLINE COMPOUNDS | TRUSTEES OF TUFTS COLLEGE (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049320-A1 | 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof | DAZAP1, DCUN1D5, DHX15 | KMT2A 2900/4885FABP5 1912/4885FABP7 3661/4885 |
| US-20250352656-A1 | SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS | NOD2, NGLY1, CGAS | KMT2A 4744/4885FABP5 3490/4885FABP7 3364/4885 |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | ADRM1, SSB, FCER2 | KMT2A 4147/4885FABP5 912/4885FABP7 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.